{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:06:40Z","timestamp":1789546000902,"version":"build-2803163510"},"reference-count":189,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["QY24058"],"award-info":[{"award-number":["QY24058"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["2127000356"],"award-info":[{"award-number":["2127000356"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["L234041"],"award-info":[{"award-number":["L234041"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403417"],"award-info":[{"award-number":["82403417"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bonr.2026.101930","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:12:12Z","timestamp":1781107932000},"page":"101930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Genomic landscape and tumor immune microenvironment of osteosarcoma: Bridging mechanistic insights to precision therapeutics"],"prefix":"10.1016","volume":"30","author":[{"given":"Chenchen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiqiu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.bonr.2026.101930_bb0005","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.bonr.2026.101930_bb0010","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s00018-015-1918-y","article-title":"Bone microenvironment signals in osteosarcoma development","volume":"72","author":"Alfranca","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.bonr.2026.101930_bb0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.mayocp.2012.01.015","article-title":"Common musculoskeletal tumors of childhood and adolescence","volume":"87","author":"Arndt","year":"2012","journal-title":"Mayo Clin. Proc."},{"issue":"10","key":"10.1016\/j.bonr.2026.101930_bb0020","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41568-024-00740-4","article-title":"CAF-induced physical constraints controlling T cell state and localization in solid tumours","volume":"24","author":"Arpinati","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.bonr.2026.101930_bb0025","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1158\/0008-5472.CAN-08-2645","article-title":"Insulin receptor isoform a and insulin-like growth factor II as additional treatment targets in human osteosarcoma","volume":"69","author":"Avnet","year":"2009","journal-title":"Cancer Res."},{"issue":"7689","key":"10.1016\/j.bonr.2026.101930_bb0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bonr.2026.101930_bb0035","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.bonr.2026.101930_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bonr.2026.101930_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15936","article-title":"Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma","volume":"8","author":"Behjati","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-deleted cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bonr.2026.101930_bb0055","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0065","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","article-title":"Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols","volume":"20","author":"Bielack","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.bonr.2026.101930_bb0070","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2014.60.0734","volume":"33","author":"Bielack","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bonr.2026.101930_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetimm.2022.110534","article-title":"Equine peripheral blood CD14(+) monocyte-derived macrophage in-vitro characteristics after GM-CSF pretreatment and LPS+IFN-\u03b3 or IL-4+IL-10 differentiation","volume":"255","author":"Bowlby","year":"2023","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"6937","key":"10.1016\/j.bonr.2026.101930_bb0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bonr.2026.101930_bb0085","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/1078-0432.CCR-10-2047","article-title":"Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents","volume":"17","author":"Buddingh","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bonr.2026.101930_bb0090","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s10637-010-9467-6","article-title":"The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines","volume":"29","author":"Budman","year":"2011","journal-title":"Investig. New Drugs"},{"issue":"4","key":"10.1016\/j.bonr.2026.101930_bb0095","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bonr.2026.101930_bb0100","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.3390\/ijms18112355","article-title":"Collateral damage intended-cancer-associated fibroblasts and vasculature are potential targets in cancer therapy","volume":"18","author":"Cavaco","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.bonr.2026.101930_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155207","article-title":"Tumor-associated macrophages in osteosarcoma: from mechanisms to therapy","volume":"21","author":"Cersosimo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.celrep.2014.03.003","article-title":"Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma","volume":"7","author":"Chen","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.bonr.2026.101930_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.12.024","article-title":"Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs","volume":"500","author":"Chen","year":"2021","journal-title":"Cancer Lett."},{"issue":"24","key":"10.1016\/j.bonr.2026.101930_bb0125","doi-asserted-by":"crossref","first-page":"13657","DOI":"10.3390\/ijms252413657","article-title":"Whole-exome analysis and osteosarcoma: a game still open","volume":"25","author":"Chiappetta","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bonr.2026.101930_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.08.014","article-title":"Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity","volume":"40","author":"Chryplewicz","year":"2022","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.bonr.2026.101930_bb0135","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-22-1471","article-title":"Ewing sarcoma and osteosarcoma have distinct immune signatures and intercellular communication networks","volume":"28","author":"Cillo","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bonr.2026.101930_bb0140","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/1541-7786.MCR-19-0541","article-title":"SRSF2 regulation of MDM2 reveals splicing as a therapeutic vulnerability of the p53 pathway","volume":"18","author":"Comiskey","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0145","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","article-title":"Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing","volume":"52","author":"Cort\u00e9s-Ciriano","year":"2020","journal-title":"Nat. Genet."},{"issue":"7383","key":"10.1016\/j.bonr.2026.101930_bb0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nature10802","article-title":"DNA breaks and chromosome pulverization from errors in mitosis","volume":"482","author":"Crasta","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bonr.2026.101930_bb0155","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/jor.24848","article-title":"Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma","volume":"38","author":"Cui","year":"2020","journal-title":"J. Orthop. Res."},{"issue":"11","key":"10.1016\/j.bonr.2026.101930_bb0160","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/s41379-022-01112-9","article-title":"Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression","volume":"35","author":"Cyrta","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bonr.2026.101930_bb0165","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2021.4","article-title":"Methylation multiplicity and its clinical values in cancer","volume":"23","author":"Dai","year":"2021","journal-title":"Expert Rev. Mol. Med."},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0170","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.bonr.2026.101930_bb0175","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41588-022-01216-7","article-title":"TP53-dependent genomic instability","volume":"54","author":"Danovi","year":"2022","journal-title":"Nat. Genet."},{"issue":"6322","key":"10.1016\/j.bonr.2026.101930_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bonr.2026.101930_bb0185","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.bonr.2026.101930_bb0190","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-20-4513","article-title":"First-in-human phase I study of ABBV-085, an antibody-drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors","volume":"27","author":"Demetri","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bonr.2026.101930_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.11.002","article-title":"Mitotic catastrophe and cancer drug resistance: a link that must to be broken","volume":"24","author":"Denisenko","year":"2016","journal-title":"Drug Resist. Updat."},{"issue":"6","key":"10.1016\/j.bonr.2026.101930_bb0200","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/cam4.1518","article-title":"Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases","volume":"7","author":"Dhupkar","year":"2018","journal-title":"Cancer Med."},{"issue":"7916","key":"10.1016\/j.bonr.2026.101930_bb0205","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41586-022-04789-9","article-title":"A pan-cancer compendium of chromosomal instability","volume":"606","author":"Drews","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0210","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bonr.2026.101930_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102154","article-title":"MYC as a target for cancer treatment","volume":"94","author":"Duffy","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.bonr.2026.101930_bb0220","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2559.2011.04023.x","article-title":"Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes","volume":"60","author":"Duhamel","year":"2012","journal-title":"Histopathology"},{"issue":"20","key":"10.1016\/j.bonr.2026.101930_bb0225","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2011.37.4546","article-title":"Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children\u2019s oncology group","volume":"30","author":"Ebb","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bonr.2026.101930_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2024.12.005","article-title":"Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution","volume":"188","author":"Espejo Valle-Inclan","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.bonr.2026.101930_bb0235","article-title":"Prognostic value of the G2 expression signature and MYC overexpression in childhood high-grade osteosarcoma","volume":"9","author":"van Ewijk","year":"2025","journal-title":"JCO Precis. Oncol."},{"issue":"17","key":"10.1016\/j.bonr.2026.101930_bb0240","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2011.38.4420","article-title":"Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG\/OS-1","volume":"30","author":"Ferrari","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0245","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.990800","article-title":"CD8(+)\/FOXP3(+)-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study","volume":"4","author":"Fritzsching","year":"2015","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.bonr.2026.101930_bb0250","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1023\/A:1008391103132","article-title":"Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group\u2019s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs","volume":"9","author":"Fuchs","year":"1998","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.bonr.2026.101930_bb0255","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.bonr.2026.101930_bb0260","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","article-title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bonr.2026.101930_bb0265","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ejca.2010.11.036","article-title":"Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials","volume":"47","author":"Gelderblom","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.bonr.2026.101930_bb0270","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1016\/j.bmcl.2011.04.005","article-title":"Synthesis of biotinylated muramyl tripeptides with NOD2-stimulating activity","volume":"21","author":"Gisch","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030423","article-title":"Characterization of macrophages and osteoclasts in the osteosarcoma tumor microenvironment at diagnosis: new perspective for osteosarcoma treatment?","volume":"13","author":"Gomez-Brouchet","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0280","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.devcel.2022.12.012","article-title":"Loss of RanGAP1 drives chromosome instability and rapid tumorigenesis of osteosarcoma","volume":"58","author":"Gong","year":"2023","journal-title":"Dev. Cell"},{"issue":"9","key":"10.1016\/j.bonr.2026.101930_bb0285","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/pbc.25074","article-title":"HER-2 expression is not prognostic in osteosarcoma; a Children\u2019s Oncology Group prospective biology study","volume":"61","author":"Gorlick","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bonr.2026.101930_bb0290","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/jcp.22411","article-title":"T cell suppression by osteoclasts in vitro","volume":"226","author":"Grassi","year":"2011","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0295","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","article-title":"Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial","volume":"16","author":"Grignani","year":"2015","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.bonr.2026.101930_bb0300","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1039\/C7RA11267J","article-title":"Inhibition of the expression of oncogene SRSF3 by blocking an exonic splicing suppressor with antisense oligonucleotides","volume":"8","author":"Guo","year":"2018","journal-title":"RSC Adv."},{"key":"10.1016\/j.bonr.2026.101930_bb0305","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.intimp.2016.01.023","article-title":"CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma","volume":"34","author":"Han","year":"2016","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0310","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"issue":"7528","key":"10.1016\/j.bonr.2026.101930_bb0315","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.bonr.2026.101930_bb0320","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1200\/JCO-24-01281","article-title":"Methotrexate, doxorubicin, and cisplatin versus methotrexate, doxorubicin, and cisplatin + ifosfamide in poor responders to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (JCOG0905): a multicenter, open-label, randomized trial","volume":"43","author":"Hiraga","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0325","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006991","article-title":"Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models","volume":"12","author":"Hu","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.bonr.2026.101930_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.04.011","article-title":"Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer","volume":"40","author":"Huang","year":"2022","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.bonr.2026.101930_bb0335","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.7150\/thno.73714","article-title":"Single-cell transcriptomics reveals the regulative roles of cancer associated fibroblasts in tumor immune microenvironment of recurrent osteosarcoma","volume":"12","author":"Huang","year":"2022","journal-title":"Theranostics"},{"issue":"7890","key":"10.1016\/j.bonr.2026.101930_bb0340","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41586-021-04116-8","article-title":"ecDNA hubs drive cooperative intermolecular oncogene expression","volume":"600","author":"Hung","year":"2021","journal-title":"Nature"},{"issue":"7793","key":"10.1016\/j.bonr.2026.101930_bb0345","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0350","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.bonr.2026.101930_bb0355","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","article-title":"Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade","volume":"82","author":"Jenkins","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0360","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1038\/s41467-022-34689-5","article-title":"Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bonr.2026.101930_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0370","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","article-title":"Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy","volume":"42","author":"Kaczanowska","year":"2024","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bonr.2026.101930_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.12.010","article-title":"MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage","volume":"39","author":"Kalev","year":"2021","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.bonr.2026.101930_bb0380","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1158\/1078-0432.CCR-20-4221","article-title":"The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models","volume":"27","author":"Kendsersky","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bonr.2026.101930_bb0385","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ijc.34027","article-title":"A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis","volume":"151","author":"Khalid","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bonr.2026.101930_bb0390","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.actbio.2022.03.044","article-title":"Microfluidic one-directional interstitial flow generation from cancer to cancer associated fibroblast","volume":"144","author":"Kim","year":"2022","journal-title":"Acta Biomater."},{"issue":"22","key":"10.1016\/j.bonr.2026.101930_bb0395","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1158\/0008-5472.CAN-23-0385","article-title":"Subclonal somatic copy-number alterations emerge and dominate in recurrent osteosarcoma","volume":"83","author":"Kinnaman","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bonr.2026.101930_bb0400","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ebiom.2019.04.009","article-title":"Combining PARP and CDK4\/6 inhibitors in MYC driven ovarian cancer","volume":"43","author":"Konecny","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bonr.2026.101930_bb0405","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-981-15-3266-5_4","article-title":"Discovery of new immune checkpoints: family grows up","volume":"1248","author":"Kong","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bonr.2026.101930_bb0410","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.1038\/ncomms9940","article-title":"Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency","volume":"6","author":"Kovac","year":"2015","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bonr.2026.101930_bb0415","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ijc.30504","article-title":"Nutlin-3a selects for cells harbouring TP53 mutations","volume":"140","author":"Kucab","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.bonr.2026.101930_bb0420","first-page":"2512","article-title":"Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor","volume":"133","author":"Kuijjer","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0425","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","article-title":"Cytokines in cancer","volume":"43","author":"Kureshi","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0430","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s13046-018-0978-x","article-title":"HDAC2 depletion promotes osteosarcoma\u2019s stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy","volume":"37","author":"La Noce","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0435","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bonr.2026.101930_bb0440","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0445","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/gcc.10291","article-title":"Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma","volume":"39","author":"Lau","year":"2004","journal-title":"Genes Chromosom. Cancer"},{"issue":"4","key":"10.1016\/j.bonr.2026.101930_bb0450","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ejca.2006.10.023","article-title":"SFOP OS94: a randomised trial comparing preoperative` high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients","volume":"43","author":"Le Deley","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.bonr.2026.101930_bb0455","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.bonr.2026.101930_bb0460","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","article-title":"Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics","volume":"17","author":"Li","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.bonr.2026.101930_bb0465","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/0008-5472.CAN-23-1448","article-title":"Spatial and single-cell transcriptomics reveal a cancer-associated fibroblast subset in HNSCC that restricts infiltration and antitumor activity of CD8+ T cells","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bonr.2026.101930_bb0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.09.044","article-title":"The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy","volume":"159","author":"Liao","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0475","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s42003-022-03117-1","article-title":"Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcoma","volume":"5","author":"Lietz","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bonr.2026.101930_bb0480","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s11658-018-0099-8","article-title":"LAMP3 plays an oncogenic role in osteosarcoma cells partially by inhibiting TP53","volume":"23","author":"Liu","year":"2018","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.bonr.2026.101930_bb0485","article-title":"Single-cell transcriptomics reveals the complexity of the tumor microenvironment of treatment-naive osteosarcoma","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0490","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1186\/s12885-021-09042-6","article-title":"Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bonr.2026.101930_bb0495","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","article-title":"Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity","volume":"19","author":"Liu","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"13","key":"10.1016\/j.bonr.2026.101930_bb0500","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.bonr.2026.101930_bb0505","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ctrv.2013.11.006","article-title":"Osteosarcoma treatment - where do we stand? A state of the art review","volume":"40","author":"Luetke","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bonr.2026.101930_bb0510","article-title":"Extrachromosomal circular DNA in cancer drug resistance and its potential clinical implications","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Oncol."},{"issue":"7696","key":"10.1016\/j.bonr.2026.101930_bb0515","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bonr.2026.101930_bb0520","article-title":"Palbociclib in solid tumor patients with genomic alterations in the cyclinD-cdk4\/6-INK4a-Rb pathway: results from National Cancer Institute-Children\u2019s Oncology Group pediatric molecular analysis for therapy choice trial arm I (APEC1621I)","volume":"8","author":"Macy","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0525","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003827","article-title":"Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling","volume":"10","author":"Makino","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bonr.2026.101930_bb0530","doi-asserted-by":"crossref","DOI":"10.1038\/srep31222","article-title":"Insulin receptor alternative splicing is regulated by insulin signaling and modulates beta cell survival","volume":"6","author":"Malakar","year":"2016","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bonr.2026.101930_bb0535","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1158\/0008-5472.CAN-20-4189","article-title":"Immune infiltrate and tumor microenvironment transcriptional programs stratify pediatric osteosarcoma into prognostic groups at diagnosis","volume":"82","author":"Marchais","year":"2022","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bonr.2026.101930_bb0540","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.bonr.2026.101930_bb0545","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","article-title":"Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders","volume":"21","author":"Maskalenko","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.bonr.2026.101930_bb0550","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/ijc.33046","article-title":"Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma","volume":"147","author":"McGuire","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.bonr.2026.101930_bb0555","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2005.06.031","article-title":"Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and\/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate","volume":"23","author":"Meyers","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bonr.2026.101930_bb0560","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children\u2019s Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bonr.2026.101930_bb0565","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bonr.2026.101930_bb0570","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamaoncol.2020.0197","article-title":"Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma","volume":"6","author":"Mirabello","year":"2020","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0575","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/path.2603","article-title":"Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2","volume":"219","author":"Mohseny","year":"2009","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0580","article-title":"Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma","volume":"6","author":"Mu","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0585","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12885-017-3046-6","article-title":"Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis","volume":"17","author":"Murahari","year":"2017","journal-title":"BMC Cancer"},{"issue":"23","key":"10.1016\/j.bonr.2026.101930_bb0590","doi-asserted-by":"crossref","first-page":"16823","DOI":"10.3390\/ijms242316823","article-title":"The future of HER2-targeted treatment for osteosarcoma: lessons from the negative trastuzumab deruxtecan results","volume":"24","author":"Nakano","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bonr.2026.101930_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061482","article-title":"Together intra-tumor hypoxia and macrophagic immunity are driven worst outcome in pediatric high-grade osteosarcomas","volume":"14","author":"Nazon","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0600","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0605","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13045-020-01012-y","article-title":"GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma","volume":"13","author":"Park","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.bonr.2026.101930_bb0610","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.21.02010","article-title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer","volume":"40","author":"Park","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0615","first-page":"66","article-title":"Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers","volume":"5","author":"Payton","year":"2024","journal-title":"Nat. Can."},{"issue":"7791","key":"10.1016\/j.bonr.2026.101930_bb0620","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0625","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1038\/s41467-025-60092-x","article-title":"Soft matrix promotes immunosuppression in tumor-resident immune cells via COX-FGF2 signaling","volume":"16","author":"Peura","year":"2025","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bonr.2026.101930_bb0630","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","article-title":"Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Piperno-Neumann","year":"2016","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.bonr.2026.101930_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310463","article-title":"Analysis of the mutational landscape of osteosarcomas identifies genes related to metastasis and prognosis and disrupted biological pathways of immune response and bone development","volume":"24","author":"Pires","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.bonr.2026.101930_bb0640","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/0008-5472.CAN-19-2843","article-title":"Tumor-derived prostaglandin E2 promotes p50 NF-\u03baB-dependent differentiation of monocytic MDSCs","volume":"80","author":"Porta","year":"2020","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bonr.2026.101930_bb0645","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1158\/0008-5472.CAN-21-3734","article-title":"Exploiting LRRC15 as a novel therapeutic target in cancer","volume":"82","author":"Ray","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bonr.2026.101930_bb0650","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4419-0284-9_4","article-title":"Osteosarcoma multidisciplinary approach to the management from the pathologist\u2019s perspective","volume":"152","author":"Raymond","year":"2009","journal-title":"Cancer Treat. Res."},{"issue":"19","key":"10.1016\/j.bonr.2026.101930_bb0655","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bonr.2026.101930_bb0660","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.18632\/oncotarget.3115","article-title":"TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome","volume":"6","author":"Ribi","year":"2015","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.bonr.2026.101930_bb0665","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1002\/cncr.32351","article-title":"Provocative questions in osteosarcoma basic and translational biology: a report from the Children\u2019s Oncology Group","volume":"125","author":"Roberts","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bonr.2026.101930_bb0670","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/path.6219","article-title":"Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway","volume":"262","author":"Saba","year":"2024","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0675","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41525-024-00430-y","article-title":"CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma","volume":"9","author":"Saba","year":"2024","journal-title":"NPJ Genom. Med."},{"key":"10.1016\/j.bonr.2026.101930_bb0680","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.894247","article-title":"Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages","volume":"9","author":"Sajjadi","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"9","key":"10.1016\/j.bonr.2026.101930_bb0685","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","article-title":"Interleukin-10 in cancer immunotherapy: from bench to bedside","volume":"9","author":"Salkeni","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0690","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/2159-8290.CD-17-1152","article-title":"Genome-informed targeted therapy for osteosarcoma","volume":"9","author":"Sayles","year":"2019","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.bonr.2026.101930_bb0695","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s10637-013-0029-6","article-title":"A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies","volume":"31","author":"Schelman","year":"2013","journal-title":"Investig. New Drugs"},{"issue":"7848","key":"10.1016\/j.bonr.2026.101930_bb0700","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41586-020-03064-z","article-title":"Chromothripsis drives the evolution of gene amplification in cancer","volume":"591","author":"Shoshani","year":"2021","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bonr.2026.101930_bb0705","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/neuonc\/noab127","article-title":"Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model","volume":"23","author":"Simovic","year":"2021","journal-title":"Neuro-Oncology"},{"issue":"2","key":"10.1016\/j.bonr.2026.101930_bb0710","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41568-024-00769-5","article-title":"Chromothripsis in cancer","volume":"25","author":"Simovic-Lorenz","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.bonr.2026.101930_bb0715","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.bonr.2026.101930_bb0720","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ijc.30778","article-title":"Genome-wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma","volume":"141","author":"Smida","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.bonr.2026.101930_bb0725","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol."},{"issue":"Pt 1","key":"10.1016\/j.bonr.2026.101930_bb0730","article-title":"Combination of lipopolysaccharide and polygalacturonic acid exerts antitumor activity and augments anti-PD-L1 immunotherapy","volume":"281","author":"Song","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.bonr.2026.101930_bb0735","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","article-title":"Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia","volume":"28","author":"Stein","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.bonr.2026.101930_bb0740","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.1158\/1078-0432.CCR-18-4032","article-title":"Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations","volume":"25","author":"Suehara","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.bonr.2026.101930_bb0745","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/1078-0432.CCR-23-3298","article-title":"Redirecting B7-H3.CAR T cells to chemokines expressed in osteosarcoma enhances homing and antitumor activity in preclinical models","volume":"30","author":"Talbot","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0750","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/jor.24227","article-title":"Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma","volume":"37","author":"Tang","year":"2019","journal-title":"J. Orthop. Res."},{"issue":"11","key":"10.1016\/j.bonr.2026.101930_bb0755","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bonr.2026.101930_bb0760","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","article-title":"Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication","volume":"28","author":"Theruvath","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bonr.2026.101930_bb0765","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pharmthera.2019.06.010","article-title":"TP53 in bone and soft tissue sarcomas","volume":"202","author":"Thoenen","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0770","doi-asserted-by":"crossref","DOI":"10.1038\/s41413-023-00246-z","article-title":"Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment","volume":"11","author":"Tian","year":"2023","journal-title":"Bone Res."},{"issue":"18","key":"10.1016\/j.bonr.2026.101930_bb0775","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1158\/0008-5472.CAN-22-1427","article-title":"Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer","volume":"82","author":"Timperi","year":"2022","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.bonr.2026.101930_bb0780","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-24-0563","article-title":"Mapping the single-cell differentiation landscape of osteosarcoma","volume":"30","author":"Truong","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0785","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0790","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00774-020-01162-6","article-title":"Osteoclast differentiation by RANKL and OPG signaling pathways","volume":"39","author":"Udagawa","year":"2021","journal-title":"J. Bone Miner. Metab."},{"issue":"3","key":"10.1016\/j.bonr.2026.101930_bb0795","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRP\u03b1-CD47 immune checkpoint blockade in anticancer therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.bonr.2026.101930_bb0800","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.annonc.2022.03.011","article-title":"Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities","volume":"33","author":"Venkataramany","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0805","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41467-020-16134-7","article-title":"The landscape of chromothripsis across adult cancer types","volume":"11","author":"Voronina","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0810","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","article-title":"RANKL-RANK signaling in osteoclastogenesis and bone disease","volume":"12","author":"Wada","year":"2006","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bonr.2026.101930_bb0815","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6649412","article-title":"Analysis of immune gene expression subtypes reveals osteosarcoma immune heterogeneity","volume":"2021","author":"Wan","year":"2021","journal-title":"J. Oncol."},{"issue":"8","key":"10.1016\/j.bonr.2026.101930_bb0820","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/abbs\/gms053","article-title":"MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells","volume":"44","author":"Wang","year":"2012","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"issue":"8","key":"10.1016\/j.bonr.2026.101930_bb0825","article-title":"B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bonr.2026.101930_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215766","article-title":"Metabolism and polarization regulation of macrophages in the tumor microenvironment","volume":"543","author":"Wang","year":"2022","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0835","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12943-022-01596-8","article-title":"Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.bonr.2026.101930_bb0840","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/annonc\/mdr491","article-title":"Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials","volume":"23","author":"Whelan","year":"2012","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.bonr.2026.101930_bb0845","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1158\/1078-0432.CCR-12-0738","article-title":"Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response","volume":"18","author":"Wong","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bonr.2026.101930_bb0850","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics","volume":"182","author":"Wu","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"7784","key":"10.1016\/j.bonr.2026.101930_bb0855","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41586-019-1763-5","article-title":"Circular ecDNA promotes accessible chromatin and high oncogene expression","volume":"575","author":"Wu","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0860","article-title":"Immuno-genomic landscape of osteosarcoma","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0865","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12929-023-00917-3","article-title":"A tumor microenvironment-based prognostic index for osteosarcoma","volume":"30","author":"Wu","year":"2023","journal-title":"J. Biomed. Sci."},{"issue":"7","key":"10.1016\/j.bonr.2026.101930_bb0870","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1200\/JCO.2005.04.074","article-title":"TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study","volume":"23","author":"Wunder","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bonr.2026.101930_bb0875","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s13277-013-1136-x","article-title":"Effect of the cytokine levels in serum on osteosarcoma","volume":"35","author":"Xiao","year":"2014","journal-title":"Tumour Biol."},{"issue":"7","key":"10.1016\/j.bonr.2026.101930_bb0880","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0542","article-title":"Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial","volume":"24","author":"Xie","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0885","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000798","article-title":"Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial","volume":"8","author":"Xie","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0890","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000798","article-title":"Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial","volume":"8","author":"Xie","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"16_suppl","key":"10.1016\/j.bonr.2026.101930_bb0895","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.11507","article-title":"ARTEMIS-002: phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma","volume":"42","author":"Xie","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.bonr.2026.101930_bb0900","doi-asserted-by":"crossref","first-page":"23662","DOI":"10.18632\/oncotarget.4282","article-title":"CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models","volume":"6","author":"Xu","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bonr.2026.101930_bb0905","article-title":"A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0910","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12885-019-6499-y","article-title":"Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells","volume":"20","author":"Yoshida","year":"2020","journal-title":"BMC Cancer"},{"issue":"49","key":"10.1016\/j.bonr.2026.101930_bb0915","doi-asserted-by":"crossref","first-page":"67225","DOI":"10.1021\/acsami.4c12532","article-title":"Photothermal-triggered extracellular matrix clearance and dendritic cell maturation for enhanced osteosarcoma immunotherapy","volume":"16","author":"Yu","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0920","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10229-8","article-title":"B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.bonr.2026.101930_bb0925","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.gendis.2023.02.028","article-title":"Cellular senescence-driven transcriptional reprogramming of the MAFB\/NOTCH3 axis activates the PI3K\/AKT pathway and promotes osteosarcoma progression","volume":"11","author":"Zhang","year":"2024","journal-title":"Genes Dis."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0930","article-title":"PD-1 axis expression in musculoskeletal tumors and antitumor effect of Nivolumab in osteosarcoma model of humanized mouse","volume":"11","author":"Zheng","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101930_bb0935","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","article-title":"Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bonr.2026.101930_bb0940","article-title":"Immune microenvironment in osteosarcoma: components, therapeutic strategies and clinical applications","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bonr.2026.101930_bb0945","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/09553000802195349","article-title":"P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2","volume":"84","author":"Zuffa","year":"2008","journal-title":"Int. J. Radiat. Biol."}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:41:46Z","timestamp":1789544506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187226000343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":189,"alternative-id":["S2352187226000343"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101930","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic landscape and tumor immune microenvironment of osteosarcoma: Bridging mechanistic insights to precision therapeutics","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101930"}}